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Abstract  
Background If loss of functioning nephrons predisposes to glomerular barotrauma (a ‘remnant 
nephron’ effect) then glomerular permeability should increase as glomerular filtration rate (GFR) falls, 
as is observed in animal models of nephron loss.  
Methods Changes in protein permeability, defined as proteinuria or albuminuria per ml/min of GFR, 
were measured in the setting of nephron loss due to kidney donation (ALTOLD cohort) or progressive 
CKD (MDRD, AASK and CRIC studies). 
Results Following kidney donation renal albumin permeability increased by 31% from predonation 
levels (p<0.001). With progression of CKD a 50% loss of residual GFR was accompanied by increases in 
proteinuria per ml/min GFR of 1.8-, 2.1-, and 1.6-fold in the MDRD, AASK and CRIC cohorts respectively 
(p<0.001 for all), independent of systolic BP changes and ACE/ARB use. A 70% reduction in GFR was 
associated with permeability increases of 3.1-, 4.4-, and 2.6-fold in the same cohorts. Among MDRD 
participants with progression of nonglomerular primary disease, the top quartile of final protein 
permeability was 141mg/ml/min. This degree of permeability would have resulted in nephrotic range 
proteinuria had it been present at the baseline mean GFR of 40ml/min, implying the development of 
de novo glomerular pathology as GFR fell. In the absence of a fall in GFR there was no increase in 
permeability. 
Conclusion Nephron loss is accompanied by a measurable increase in albuminuria which can be 
explained by increased glomerular protein permeability, even in the absence of a primary glomerular 
disease. This is consistent with a remnant nephron effect in human CKD. 
 
 
 
Introduction 
Animal models have demonstrated a maladaptive ‘remnant nephron effect’ whereby a substantial loss 
of nephron mass leads to glomerular hypertension within the surviving nephrons, thereby reinforcing 
kidney injury, resulting in nephron dropout, and further loss in GFR.1, 2 The extent to which this 
phenomenon contributes to the progression of human Chronic Kidney Disease (CKD) is unclear. If loss 
of functioning nephron mass in humans predisposes to barotrauma from hypertension in the surviving 
glomeruli, then the protein leak per nephron should increase, as is observed in 5/6 rat nephrectomy 
model.2 Single nephron protein excretion cannot be measured clinically, but proteinuria per ml/min 
of glomerular filtration rate (GFR) is a logical measure of glomerular permeability;3 GFR is both the 
driving force for convective protein loss and a surrogate for the glomerular surface area across which 
protein loss can occur. We therefore studied the change in protein leak per ml/min of GFR following 
kidney donation (the Assessing Long Term Outcomes in Living Kidney Donors (ALTOLD) study cohort) 
or progressive loss of excretory function (the Modification of Diet in Renal Disease (MDRD), African 
American Study of Kidney Disease (AASK) and Chronic Renal insufficiency Cohort (CRIC) studies). We 
hypothesized that nephron loss would be accompanied by an increase in proteinuria per ml/min of 
GFR, even in the absence of a primary glomerular pathology affecting  the filtration barrier.  
 
Methods 
Study cohorts 
The inclusion criteria and data collection procedures of the ALTOLD, MDRD, AASK and CRIC studies 
have been reported previously.4-7 Data were provided for this analysis by the National Institute of 
Diabetes, Digestive and Kidney Disease Central Repository following local Institutional Review Board 
Approval. The ALTOLD study ascertained the impact of kidney donation on GFR, protein excretion and 
blood pressure over a 3y period among 182 kidney donors and 173 healthy controls.4 The MDRD study 
investigated the effect of a low protein diet and lower mean arterial blood pressure target (92 vs 
107mmHg; 2x2 factorial design) on GFR loss among 840 participants with CKD.5, 8 In the AASK study, 
1094 African American patients with hypertensive nephropathy were randomized to antihypertensive 
regimes targeting a standard or more intensive control of mean arterial pressure (102-107mmHg vs 
≤92mmHg) and based on initial treatment with ramipril, amlodipine, or metoprolol (3x2 factorial 
design).6, 9 The CRIC study is an ongoing prospective observational investigation of risk factors for CKD 
progression and cardiovascular disease in a cohort of 3939 participants with CKD.7, 10 
 
Measurements 
GFR was measured by iohexol clearance (ALTOLD) or iothalamate clearance (MDRD, AASK and CRIC). 
Protein permeability was assessed in MDRD, AASK and CRIC participants as 24h proteinuria per ml/min 
GFR using urine and GFR measurements from the same study visit. Urine collections with a creatinine 
excretion rate of <350mg/24h or >3500mg/24h were considered implausible and not included in the 
analyses.11 In ALTOLD timed urine collections were not undertaken so relative changes in permeability 
were assessed using spot urine albumin:creatinine ratio (ACR) per ml/min GFR. Fractional excretion of 
albumin was used as an additional measure of permeability in ALTOLD since any reduction in muscle 
mass (thus creatinine excretion rate) following kidney donation could increase ACR independently of 
albuminuria. ALTOLD cohort analyses included all participants with complete GFR, ACR and blood 
pressure data for each timepoint (0, 6, 12, 24 and 36m). In the CKD cohorts, participants with at least 
2 paired measurements of proteinuria and GFR and concomitant BP results were included. 
 
Kidney Disease Diagnosis 
A range of renal diagnostic categories were recorded for MDRD study participants. For the purposes 
of this analysis, the cohort was divided into subgroups with a primary glomerular disease (including 
membranous, membranoproliferative, focal sclerosis, mesangial proliferative, IgA and other 
glomerulonephritides, nonbiopsied nephrotic syndrome, immunotactoid, amyloid, Wegener’s, 
Alport’s, diabetic nephropathy), those with a diagnosis not intrinsically affecting the glomerular 
permeability barrier (including polycystic kidney disease, interstitial nephritis, nephrocalcinosis, 
lithium toxicity, previous tubular necrosis, medullary sponge kidney, hypertension, atherosclerosis), 
those with an unknown diagnosis and those with a secondary diagnosis of focal sclerosis in the 
absence of primary glomerular disease. This latter category was selected since secondary focal 
sclerosis is considered a manifestation of remnant glomerular hypertension. The CRIC cohort utilised 
4 diagnostic categories: diabetes, hypertension, other (including glomerulonephritis) and unknown. 
All patients in the AASK cohort had an underlying diagnosis of hypertensive nephropathy made on 
clinical grounds.12 
 
Statistical analyses  
Fractional change in proteinuria  was expressed as final permeability/baseline permeability and log 
transformed prior to parametric analyses. Sequential changes in GFR, ACR and permeability following 
kidney donation in ALTOLD were examined using repeated measures ANOVA. In the CKD cohorts, 
definite evidence of disease progression was defined as a reduction in GFR of at least 30% from 
baseline to final available assessment. Visual inspection of the data (Loess curves) identified a steeper 
increase in log fractional change in permeability associated with more severe relative reductions in 
GFR. Regression of log transformed permeability change against the square of the percentage fall in 
GFR was therefore undertaken. This better approximated a linear relationship (based on R2 values and 
visual inspection) in all the CKD cohorts. Data are thus presented from this approach. Other variables 
included a priori were systolic BP and change in systolic BP from baseline,13 use of ACE inhibitor or 
angiotensin receptor blocker, treatment arm (MDRD and AASK trials) and renal diagnosis (where 
applicable). Interaction between baseline GFR and percentage GFR reduction were examined using 
multiplicative interaction terms. Analyses were performed using SPSS version 25.0 (IBM Corp., 
Armonk, N.Y., USA). 
 
Results 
Participant characteristics 
Characteristics of the full ALTOLD, MDRD, AASK and CRIC study cohorts have been published 
previously.4, 8-10 The characteristics of those participants donating a kidney or experiencing a fall in GFR 
of at least 30% are shown in Table 1.  
 
Changes in albumin permeability following kidney donation 
As previously reported, following kidney donation GFR fell by a median of 26% at 3 years and ACR 
decreased by 10% at 3 years, but rose steadily between 6 months and 3 years.  There was a progressive 
rise in renal albumin permeability over the 3 years following donation, to a final median increment of 
31% (geometric mean 35%, 95% CI ±14% p<0.001, Figure 1). This was not driven by a rise in 
postdonation BP, since BP did not increase (Table 1) and correction for a  change in MAP in the model 
did not affect the findings. Using fractional albumin excretion to define permeability gave the same 
conclusions (final permeability rise 33%, p<0.001).  In contrast, renal albumin permeability in controls 
did not change (median difference +1.7%). 
 
Changes in protein permeability in progressive CKD 
In participants with progressive CKD (GFR loss ≥30%) from the MDRD, AASK and CRIC cohorts absolute 
proteinuria increased (Table 1), reflecting an increase in permeability. There was a linear relationship 
between log transformed fractional change in permeability and the square of the percentage fall in 
GFR (Figure 2A-C). This relationship was consistent between cohorts and remained significant 
following adjustment for systolic BP, change in systolic BP from baseline, ACEi/ARB use, trial diet/BP 
randomisation arm and diagnostic category (p<0.001 in all cohorts, Table 2). Increasing permeability 
was not dependent on the presence of progressive primary glomerular disease, since increases were 
similar among MDRD participants with or without glomerular disease. Even among MDRD progressors 
without primary glomerular disease the top quartile of protein permeability at final assessment 
(141mg per ml/min) would equate to protein excretion of 5.6g/24h had it been present at the baseline 
GFR of 40ml/min, thus well within the ‘nephrotic range’. The top quartile of permeability at final 
assessment among AASK progressors was similar (116mg per ml/min). In contrast, in the absence of 
GFR loss there was no increase in permeability (median permeability changes was 0.9-, 1.1- and 1.0-
fold in MDRD, AASK and CRIC respectively). 
Among the small subset of nephrotic progressors (baseline proteinuria ≥3.5g/24 and serum 
albumin<35g/l, n=21 in CRIC and n=16 in MDRD) increasing permeability limited the resolution of the 
nephrotic state. In CRIC, despite a fall in median GFR from 50ml/min/1.73m2 to 23ml/min/1.73m2, 
median proteinuria only fell from 5.2g/24 to 5.1g/24h and serum albumin increased modestly from 
31 to 33g/L. In MDRD, a fall in median GFR from 31ml/min/1.73m2 to 13ml/min/1.73m2 was 
accompanied by a fall in proteinuria from 5.4g/24h to 4.1g/24h and a slight rise in serum albumin from 
33 to 34g/L. 
Some participants with progressive CKD had no increase in permeability; 16%, 22% and 24% in the 
MDRD, AASK and CRIC cohorts respectively. Since upstream occlusive vascular disease might limit 
pressure transmission to the glomerulus, age and a history of cardiovascular disease were tested as 
possible negative predictors of increasing permeability. There were no significant associations with 
these predictors in all CKD cohorts. An increase in permeability was also not confined to participants 
reaching a GFR below a threshold level; in all CKD cohorts there was no interaction between the 
absolute GFR and the percentage change in GFR. 
 
Relationship to Blood Pressure 
Since nephron loss has been hypothesized to leave remnant glomeruli more vulnerable to 
transmission of elevated systemic BP, the relationship between GFR loss, BP and permeability was 
studied. Increases in systolic BP of 20mmHg and 40mmHg were associated with permeability increases 
at final follow up of 1.5- and 2.3-fold in MDRD, 1.2- and 1.4-fold in AASK and 1.3- and 1.7-fold in CRIC 
(p<0.05 for all in adjusted models). The use of an ACE inhibitor or angiotensin receptor blocker was 
associated with a significantly smaller increase in permeability only in the MDRD study (0.76-fold, 
p=0.007). There was no significant interaction between GFR reduction and systolic BP or ACEi/ARB use 
in any cohort.  
 
Discussion 
Haemodynamic changes at remnant nephrons have been considered to play an important role in the 
progression of CKD of diverse aetiologies.14 However, the animal models used to demonstrate this 
phenomenon undergo a sudden and drastic reduction in functional nephron mass (typically 5/6  loss 
through surgical ligation of renal artery branches, or surgical removal of renal tissue). In clinical 
practice CKD develops more slowly and may be accompanied by upstream vascular 
disease/remodelling that could limit the transmission of systemic arterial pressure to the glomerular 
microcirculation. Some cases of human CKD resulting from non-glomerular disease are accompanied 
by proteinuric secondary focal segmental glomerulosclerosis, suggesting that remnant glomerular 
barotrauma can indeed occur. Whether or not the remnant nephron effect is a frequent contributor 
to progression of  human CKD  is unclear.  
We find that proteinuria increases in over 75% of cases of nephron loss, due to kidney donation or 
CKD progression. These data are in keeping with a model in which loss of nephron mass results in 
increased glomerular permeability of remnant nephrons. The top quartile of permeability among 
progressors without primary glomerular disease from the MDRD study would have been sufficient to 
cause ‘nephrotic range’ proteinuria had it been present at the baseline level of GFR. This implies that 
de novo glomerular injury commonly develops as GFR falls, consistent with a remnant nephron effect. 
Although there was no evidence of a threshold level of GFR below which permeability increased, much 
greater changes accompanied more substantial relative reductions in GFR. Thus, the increase in 
permeability following kidney donation was modest, consistent with the fact that loss of a single 
kidney does not initiate progressive injury. Glomerulomegaly and increased perfusion rather than 
glomerular hypertension are considered to account for postdonation hyperfiltration15, which may 
increase glomerular permeability via effects of shear stress on podocytes.16  
Average increases in protein permeability accompanying CKD progression were less than those 
observed in animal remnant nephron models, where permeability following 5/6 nephrectomy is often 
more than 10-fold baseline.2 Considering the observed relationship between systolic BP and 
permeability, if hypertension had been less well controlled then permeability increases might have 
been similar to those seen in the animal models, which are accompanied by severe hypertension.17 
Attenuated changes in permeability in non-hypertensive renal ablation models are similar to those we 
report in these cohorts.18 Indeed, some have argued that increased vulnerability of the glomerular 
microcirculation to systemic arterial pressure is entirely responsible for the remnant nephron 
phenomenon.17, 19, 20 Consistent with this hypothesis, a steeper relationship between systolic BP and 
renal albumin permeability was evident at lower eGFR in a cross sectional US population cohort 
analysis.21 In the current study we did not find evidence that a lower GFR sensitized the kidney to 
systolic BP since there was no interaction between GFR and systolic BP in relation to changing 
permeability. However, the cohorts studied may have had insufficiently broad ranges of systolic BP 
and GFR to identify such a phenomenon. The use of ACE inhibitors and ARBs in the CKD cohorts may 
be another reason why permeability increases were less than those in animal models, though again 
there was no evidence of an interaction between ACEi/ARB use and GFR loss. It is possible that 
increasing permeability accompanying CKD progression reflects structural changes at sclerosing 
glomeruli rather than glomerular hypertension. However, previous micropuncture studies localised 
albuminuria to remnant glomeruli with less histological evidence of structural abnormalities.2 
A minority of progressors experienced no increase in permeability. Whilst upstream vascular disease 
could limit glomerular hypertension, in exploratory analyses there was no evidence that age or 
cardiovascular disease predicted less increase in permeability. Nevertheless, these factors may have 
been poor predictors of vascular disease in the cohorts studied. (All AASK participants had 
hypertensive end organ damage so some degree of vascular remodelling would be expected to be 
universal and not necessarily predicted by age to the same extent as in other populations.) In patients 
with CKD due to  ischaemia it would be envisaged that remnant nephron haemodynamics may not 
apply.  
Although absolute protein excretion is used as a clinical tool, it would seem more logical to consider 
protein excretion in relation to GFR, given that an identical measurement of proteinuria  occurring at 
half the GFR should reflect double  the glomerular permeability.3, 22 The clinical pathophysiological 
relevance of glomerular proteinuria does not reflect absolute protein loss, but rather permeability 
changes resulting from pathology at the filtration barrier, whether of haemodynamic, immunological, 
genetic or other origin. Altered tubular protein reabsorption or loss may underlie proteinuria but 
logically this too should be indexed to the number of nephrons across which the protein loss occurs.  
 A limitation of our analyses is the use of total protein rather than albumin in the CKD cohorts, so that 
it is not possible to distinguish glomerular versus tubular source. Our use of the term ‘permeability’ in 
these analyses should strictly be interpreted in terms of the whole nephron since protein leak could 
reflect reduced tubular reabsorption. However, the extent to which protein loss per ml/min GFR 
increases strongly implies a glomerular origin in keeping with remnant nephron physiology.  
In conclusion, we find that proteinuria markedly increases with nephron loss, even in the absence of 
primary glomerular disease. This is can be explained by an increase in glomerular permeability of 
remnant nephrons, as observed in the animal models cited above.  Because more than 75% of people 
were in the studied cohorts were affected, we suggest that  haemodynamic changes in remnant 
glomeruli are  likely to be a common feature in human CKD.  
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Table 1. Characteristics of the ALTOLD Kidney Donor Cohort and of Participants with at least 30% 
Loss of GFR in the MDRD, AASK and CRIC Study Cohorts 
 
 
ALTOLD 
donors 
MDRD AASK CRIC 
N 120 371 320 193 
Age at baseline, y 43 (11) 49 (12) 53 (11) 56 (12) 
Duration of 
follow up, y 
3 2.3 (0.9) 3.7 (1.5) 3.1 (1.1) 
CKD diagnoses None Various 
Hypertensive 
nephropathy 
Various 
Baseline GFR, 
ml/min/1.73m2 
109 (18) 27 (20, 37) 42 (30, 53) 47 (32, 58) 
Diabetes, % 0 5.9 0 46.1 
Final GFR, 
ml/min/1.73m2 
79 (14) 12 (9, 19) 19 (13, 29) 25 (17,34) 
Baseline 
proteinuria, 
g/24h or ACR, 
mg/g 
4.7 (3.3, 6.4) 0.71 (0.13, 2.18) 0.34 (0.09, 1.25) 0.68 (0.13, 2.64) 
Final proteinuria, 
g/24h or ACR, 
mg/g 
4.2 (2.9, 6.9) 1.00 (0.20, 2.57) 0.57 (0.15, 1.96) 0.81 (0.17, 2.96) 
Baseline BP, 
mmHg 
118(12)/70(10) 136(18)/83(9) 151(22)/96(14) 133(22)/74(14) 
Endpoint BP, 
mmHg 
118(12)/72(8) 136(19)/80(10) 136(20)/81(13)  133(22)/72(13) 
Previous 
cardiovascular 
disease, % 
0 12.7 49.1 26.9 
On ACEi/ARB at 
baseline, % 
Nil 37.5 35.0 73.2 
On ACEi/ARB at 
follow up, % 
Nil 38.0 40.3 73.4 
 
 
Data presented as percentage, mean (SD) or median (IQR) as appropriate. 
  
Table 2. Renal protein permeability changes and their association with GFR loss in MDRD, AASK 
and CRIC study participants with progressive CKD. 
 
 
MDRD 
all 
MDRD 
nonglomerular 
disease 
MDRD 
glomerular 
disease 
MDRD 
focal 
sclerosis 
AASK CRIC 
N 371 251 71 32 320 193 
Baseline 
protein 
permeability, 
mg/ml/min 
23.7 (4.4, 
79.0) 
10.1 (2.6, 
44.5) 
76.7 (32.3, 
132.1) 
79.1 
(59.1, 
120.5) 
7.9 (1.7, 
32.6) 
13.6 (2.6, 
52.7) 
Final protein 
permeability, 
mg/ml/min 
74.5 (14.2, 
194.8) 
41.7 (8.5, 
141.1) 
154.6 
(69.7, 
287.1) 
259.8 
(148.0, 
394.8) 
27.1 (5.9, 
115.7) 
27.9 (5.1, 
121.1) 
Permeability 
fold change 
per 30% fall in 
GFR* 
1.23 (1.16, 
1.31) 
1.24 (1.15, 
1.32) 
1.28 (1.08, 
1.53) 
1.37 
(1.16, 
1.61) 
1.31 (1.22, 
1.41) 
1.19 
(1.06, 
1.33) 
Permeability 
fold change 
per 50% fall in 
GFR* 
1.79 (1.51, 
2.13) 
1.79 (1.47, 
2.20) 
2.00 (1.24, 
3.24) 
2.39 
(1.51, 
3.78) 
2.12 (1.72, 
2.62) 
1.61 
(1.18, 
2.22) 
Permeability 
fold change 
per 70% fall in 
GFR* 
3.14 (2.26, 
4.41) 
3.16 (2.13, 
4.68) 
3.90 (1.52, 
10.00) 
5.53 
(2.24, 
13.56) 
4.39 (2.91, 
6.62) 
2.56 
(1.38, 
4.77) 
 
*Adjusted for final systolic BP, change in systolic BP from baseline, ACE/ARB use, diagnosis category 
(CRIC only) and study intervention arm (MDRD and AASK). Protein permeability presented as median 
(IQR) and fold-change as adjusted coefficient (95% CI). 
 
 
 
 
 
  
Figure Legends 
 
 
Figure 1. Changes in GFR, albuminuria and albumin permeability following kidney donation in the 
ALTOLD cohort. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Changes in protein permeability in relation to percentage reduction in GFR in A) MDRD 
study participants with nonglomerular primary disease, B) AASK study participants and C) CRIC 
study participants. 
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